PTC Therapeutics (PTCT) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has maintained its negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nonsense mutation Duchenne Muscular Dystrophy, or nmDMD, following re-examination. The opinion will now be reviewed by the European Commission which is expected to decide on opinion adoption in approximately 67 days.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC announces FDA review date for NDA of sepiapterin
- PTC Therapeutics price target raised to $30 from $28 at BofA
- Biotech Alert: Searches spiking for these stocks today
- PTC Therapeutics price target raised to $45 from $32 at Morgan Stanley
- PTC Therapeutics reports ‘positive’ results from LT studies, says Baird